Known targets — ChEMBL curated mechanism
CACNA1CCACNA1DCACNA1FCACNA1SDRD2HTR1BHTR1DHTR1F
The experimentally established mechanism targets of Malic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.46 |
| ▸ | TET2 | Q6N021 | 6/20 | 0.34 |
| ▸ | TET3 | O43151 | 2/20 | 0.34 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.34 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.33 |
| ▸ | KMO | O15229 | 1/20 | 0.33 |
| ▸ | KDM4A | O75164 | 2/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.32 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.32 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.32 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | PTPRA | P18433 | 1/20 | 0.31 |
| ▸ | MMP12 | P39900 | 1/20 | 0.30 |
| ▸ | MMP13 | P45452 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Imidazole SCHEMBL10691122 | 0.84 | OR51E2 (0.52) | SMN1; SMN2ALDH1A1FKBP5TBXAS1OR51E2 | |
| Aspartic Acid SCHEMBL28155193 | 0.81 | ALDH1A1 (0.45) | ALDH1A1FKBP5 | |
| Bromoacetic Acid SCHEMBL16859465 | 0.79 | ALDH1A1 (0.56) | ALDH1A1FKBP5 | |
| Cadaverine Tartrate SCHEMBL7571787 | 0.79 | ALDH1A1 (0.56) | ALDH1A1FKBP5 | |
| Cadaverine Tartrate SCHEMBL5241549 | 0.79 | ALDH1A1 (0.56) | ALDH1A1FKBP5 | |
| Lactic Acid SCHEMBL1331765 | 0.77 | ALDH1A1 (0.54) | ALDH1A1FKBP5 | |
| Glycolic Acid SCHEMBL31731101 | 0.77 | ALDH1A1 (0.59) | ALDH1A1FKBP5 | |
| Malonic Acid SCHEMBL14695335 | 0.77 | ALDH1A1 (0.59) | ALDH1A1FKBP5 | |
| Succinic Acid SCHEMBL9725171 | 0.77 | ALDH1A1 (0.59) | ALDH1A1FKBP5TBXAS1OR51E2 | |
| Malic Acid SCHEMBL29904179 | 0.77 | SMN1; SMN2 (0.68) | SMN1; SMN2TET2TET3TET1KMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4069309-A1 | SORTILIN BINDING CONJUGATE COMPOUNDS, COMPOSITIONS AND USES THEREOF FOR TREATING CANCER | THERATECHNOLOGIES INC. (CA) | 2022-10-12 | — | — | EP | claimed |
| CN-114980932-A | SORTILIN-binding conjugate compounds, compositions thereof, and their use for treating cancer | 瑟瑞技术公司 | 2022-08-30 | — | — | CN | claimed |
| EP-2078091-A2 | CRYSTALS AND STRUCTURE OF HUMAN IgG Fc VARIANT | Medimmune, LLC (US) | 2009-07-15 | — | — | EP | claimed |
| WO-2009009103-A2 | CRYSTALS AND STRUCTURE OF HUMAN IgG Fc VARIANT | MEDIMMUNE, LLC (US) | 2009-01-15 | — | — | WO | claimed |
| US-20230036041-A1 | SORTILIN BINDING CONJUGATE COMPOUNDS, COMPOSITIONS AND USES THEREOF FOR TREATING CANCER | THERATECHNOLOGIES INC. (CA) | 2023-02-02 | — | — | US | disclosed |
| EP-4069309-A1 | SORTILIN BINDING CONJUGATE COMPOUNDS, COMPOSITIONS AND USES THEREOF FOR TREATING CANCER | THERATECHNOLOGIES INC. (CA) | 2022-10-12 | — | — | EP | disclosed |
| CN-114980932-A | SORTILIN-binding conjugate compounds, compositions thereof, and their use for treating cancer | 瑟瑞技术公司 | 2022-08-30 | — | — | CN | disclosed |
| EP-3980126-A1 | BENZO[H][1,6] NAPHTHYRIDIN-2(1H)-ONES AS BMX INHIBITORS, FOR USE AGAINST CANCER | Instituto de Medicina Molecular João Lobo Antunes (PT) | 2022-04-13 | — | — | EP | disclosed |
| CN-114206867-A | Benzo [ H ] [1,6] naphthyridin-2 (1H) -ones as BMX inhibitors for combating cancer | 医学分子研究所 | 2022-03-18 | — | — | CN | disclosed |
| WO-2020245430-A1 | BENZO[H][1,6] NAPHTHYRIDIN-2(1H)-ONES AS BMX INHIBITORS, FOR USE AGAINST CANCER | INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANTUNES (PT) | 2020-12-10 | — | — | WO | disclosed |
| US-9376479-B2 | Human growth hormone crystals and methods for preparing them | Anjinomoto Althea, Inc. (US) | 2016-06-28 | — | — | US | disclosed |
| EP-2460530-A2 | Human growth hormone crystals and methods for preparing them | Althea Technologies, Inc. (US) | 2012-06-06 | — | — | EP | disclosed |
| EP-1581251-A2 | HUMAN GROWTH HORMONE CRYSTALS AND METHODS FOR PREPARING THEM | Altus Pharmaceuticals Inc. (US) | 2005-10-05 | — | — | EP | disclosed |
| US-20050003347-A1 | Domain-exchanged binding molecules, methods of use and methods of production | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-01-06 | — | — | US | disclosed |
| WO-2004101738-A2 | DOMAIN-EXCHANGED BINDING MOLECULES, METHODS OF USE AND METHODS OF PRODUCTION | THE SCRIPPS RESEARCH INSTITUTE (US) | 2004-11-25 | — | — | WO | disclosed |
| US-20040209804-A1 | Human growth hormone crystals and methods for preparing them | AJINOMOTO ALTHEA INC. | 2004-10-21 | — | — | US | disclosed |
| WO-2004060310-A2 | HUMAN GROWTH HORMONE CRYSTALS AND METHODS FOR PREPARING THEM | ALTUS PHARMACEUTICALS INC. (US) | 2004-07-22 | — | — | WO | disclosed |
| EP-1360349-A1 | SYSTEM AND METHOD FOR SCREENING OF NUCLEATION TENDENCY OF A MOLECULE IN A LEVITATED DROPLET | Chemical Holovoice AB (SE) | 2003-11-12 | — | — | EP | disclosed |
| US-20030049642-A1 | Screening system | NILSSON STAFFAN (SE) | 2003-03-13 | — | — | US | disclosed |
| WO-2002057520-A1 | SYSTEM AND METHOD FOR SCREENING OF NUCLEATION TENDENCY OF A MOLECULE IN A LEVITATED DROPLET | CHEMICAL HOLOVOICE AB (SE) | 2002-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230036041-A1 | SORTILIN BINDING CONJUGATE COMPOUNDS, COMPOSITIONS AND USES THEREOF FOR TREATING CANCER | SORT1, NGLY1, SNX9 | SMN1; SMN2 2079/4885ALDH1A1 4701/4885FKBP5 4183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.